Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful diligently but unsuccessfully to create a single therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past several shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What To Do When It’s Too Good In order to Be True?”, set away all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing image in the Uptick Newswire employment interview which I came away with a poor impression of the company.

Irony of irony, my bad impression of the business has grown steadily, though the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of this expertise and also linked intellectual property coming from Progenics to CytoDyn, as well as roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) along with the first new drug application approval ($five million), and also royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to get a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and numerous indications, it’s this single therapy as well as a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an active business with diverse interests albeit centered on leronlimab, several illness sorts, multiple delivering presentations in addition to multiple publications.

Might all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself with the very start of my interest in this company. Judging by the multiples of a huge number of several commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *